נאופרו 8 מ"ג / 24 שעות

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

ROTIGOTINE 8 MG / 24 HOUR

Disponible depuis:

CTS LTD

Code ATC:

N04BC09

forme pharmaceutique:

PATCHES

Mode d'administration:

TRANSDERMAL

Fabriqué par:

UCB MANUFACTURING IRELAND LTD

Groupe thérapeutique:

ROTIGOTINE

indications thérapeutiques:

Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Date de l'autorisation:

2012-09-01